Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancers, Metastatic Gastric Cancers
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable…
- Conditions
- Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers
- Trial name
- MOMENTUM1 (NCT01843725)
- Testing
- capecitabine, aflibercept
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Neoplasm Metastasis, Colorectal Neoplasms
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer…
- Conditions
- Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
- Trial name
- NCT02124148
- Testing
- Prexasertib, Cisplatin, Cetuximab
- Where
- 5 sites in United States
- Volunteers
- 167 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan…
- Trial name
- NCT00508404
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 154 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab…
- Trial name
- NCT00145314
- Testing
- FLOX (5-fluorouracil/folinic acid/oxaliplatin), FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab, FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab
- Where
- Norway
- Volunteers
- 571 people
- Sponsor
- The Nordic Colorectal Cancer Biomodulation Group
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Oligometastases
SABR-SCAN Trial for Pulmonary Oligometastases
Rationale: SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides surgical resection for limited lung metastases (oligometastases) from colorectal cancer.
- Trial name
- SABR-SCAN (NCT02414334)
- Testing
- Stereotactic Ablative Radiotherapy (SABR)
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Colonic Cancer, Metastasis
Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6…
- Trial name
- CUFOX (NCT01490996)
- Testing
- Oral complex C3 curcumin + chemotherapy, Chemotherapy only
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Leicester
Colorectal Cancer Metastatic
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic…
- Trial name
- METIMMOX (NCT03388190)
- Testing
- Nivolumab, FLOX
- Where
- 5 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Metastatic Colorectal Cancer
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line…
- Trial name
- NCT00457691
- Testing
- 5 fluorouracil, irinotecan, levo- leucovorin
- Where
- 132 sites in Argentina, Australia and 32 more
- Volunteers
- 768 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient
This is a phase II randomized study of 4-months induction first-line chemotherapy with FOLFOXIRI + cetuximab followed by maintenance with cetuximab or bevacizumab in patients affected by KRAS wild type (wt) mCRC.
- Trial name
- MACBETH (NCT02295930)
- Testing
- folfoxiri+cetuximab+surgery+cetuximab, folfoxiri+cetuximab+surgery+bevacizumab
- Where
- 22 sites in Italy
- Volunteers
- 143 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer Metastatic
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).
Background Hepatic metastases of colorectal cancer (MCC) is quite common and is a major source of morbidity and mortality. There has been evidence to show that hepatic arterial chemoembolisation using DC beads (drug eluting…
- Trial name
- NCT02350400
- Testing
- DEBIRI
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer With Liver Metastasis
Prospective Phase II Trial on Prophylactic Perihepatic Lymphadenectomy in Patients With Colorectal Cancer With Liver Metastasis
Objective: To evaluate the role of regional lymphadenectomy in patients with colorectal cancer liver metastasis. Background: Lymph node status is 1 of the most important prognostic factors in oncologic surgery; however, the role…
- Trial name
- LN (NCT01565811)
- Testing
- perihepatic lymphadenectomy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Gachon University Gil Medical Center
Colorectal Cancer
BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have recurrent or…
- Trial name
- NCT00022477
- Testing
- BMS-247550
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Chicago
Breast Cancer, Colorectal Cancer
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
The aim of the study is to determine blood concentration evolution of capecitabine and its active metabolites, in elderly patient 75 years and more.
- Trial name
- capagec (NCT00812864)
- Testing
- Capecitabine
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Limoges
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.